Ph.D., University of Hamburg, Germany, Immunology, 2003.
M.S., University of Braunschweig, Germany, Study of Biotechnology, 1996.
My research addresses the influence of HIV sequence diversity on its recognition by cytotoxic T lymphocytes, as well as the factors governing the recognition of sequence variants both in HIV-infected subjects and in vaccine trial participants. More recently, my research also includes the assessment of immune responses to viral vectors used as immunogens in HIV vaccine trials to help understand how pre-existing cellular immunity to the vector influences the quality of vaccine-induced immune responses. In my role as the Associate Laboratory Director for the HVTN, I provide leadership and scientific support for the HVTN Laboratories. This includes (but is not restricted to) oversight of the Endpoints Laboratory, which is responsible for the generation of validated immunogenicity data for all HVTN trials, and of the R&D Laboratory, which provides ancillary and exploratory data leading to a more complete view of the immune responses generated by HIV vaccines.
(Reading, Writing, Speaking)
German: (Fluent, Fluent, Fluent)
Portuguese (Brazilian): (Fluent, Fluent, Fluent)
2008-2013, Assistant member, Fred Hutchinson Cancer Research Center, Clinical Research Division and Vaccine and Infectious Disease Division
2006-2008, Instructor, Harvard University, Medical School
2006-2008, Assistant in Immunology, Massachusetts General Hospital, Partners AIDS Research Center, Infectious Diseases
2001-2006, Post-doctoral fellow, Harvard University, Medical School
2001-2006, Post-doctoral fellow, Massachusetts General Hospital, Partners AIDS Research Center, Infectious Diseases
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).. Open forum infectious diseases. 2(3):ofv082.. 2015.
COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology.. 2015.
Use of placebos in Phase 1 preventive HIV vaccine clinical trials.. Vaccine. 33(6):749-52.. 2015.
Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.. PLoS pathogens. 11(2):e1004658.. 2015.
Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.. Journal of virology.. 2014.
Increased Sequence Coverage through Combined Targeting of Variant and Conserved Epitopes Correlates with Control of HIV Replication.. Journal of virology. 88(2):1354-65.. 2014.
Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1.. Molecular therapy : the journal of the American Society of Gene Therapy. 22(2):464-75.. 2014.
Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.. Journal of immunological methods.. 2014.
The Antiviral Efficacy of CD8+T Cells in Early HIV-1 Infection Is Dependent on Targeting of Low Entropy Regions of the Viral Proteome. AIDS Research and Human Retroviruses. 29:A131-A131.. 2013.
Association of Fc gamma RIIC Polymorphism with Vaccine Efficacy and Correlates of HIV-1 Infection Risk in RV144. AIDS Research and Human Retroviruses. 29:A178-A179.. 2013.
Effective Antiviral CD8+T Cells Responses Are Rare in HIVPositive Step & Phambili Study Participants but Are Targeted to Low Entropy Viral Epitopes. AIDS Research and Human Retroviruses. 29:A20-A20.. 2013.
Extensive Yet Ineffective Gag Epitope Variant Recognition Observed in HIV-Progressors. AIDS Research and Human Retroviruses. 29:A127-A127.. 2013.
The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial. AIDS Research and Human Retroviruses. 29:A7-A8.. 2013.
HVTN 505: Efficacy of a Multi-Gene DNA Prime/Recombinant Adeno 5 (rAd5) Vector Boost Vaccine in Men & Transgender Women (TGW) Who Have Sex with Men. AIDS Research and Human Retroviruses. 29:A172-A172.. 2013.
HVTN-Tested Candidate HIV Vaccines Induce Early, Antigen-Specific Plasmablast- and Tfh-like Responses in Peripheral Blood. AIDS Research and Human Retroviruses. 29:A143-A144.. 2013.
Immune-Correlates Analysis of the Step HIV Vaccine Efficacy Trial-A Post-Hoc Analysis of HIV-Specific and Non-specific Cellular Immune Responses. AIDS Research and Human Retroviruses. 29:A119-A119.. 2013.
Immunogenicity of Homologous and Heterologous Regimens of Ad26-Enva.01 and Ad35-Enva HIV Vaccines in HIV-Uninfected Volunteers in the US and Africa. AIDS Research and Human Retroviruses. 29:A69-A69.. 2013.
No Increase in Activated T Cells and Limited Increase in Adenovirus-Specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization. AIDS Research and Human Retroviruses. 29:A180-A181.. 2013.
A Recombinant Vesicular Stomatitis Virus (rVSV) HIV-1 Gag Vaccine Is Safe and Immunogenic in Healthy, HIV-1 Uninfected Phase I Trial Participants. AIDS Research and Human Retroviruses. 29:A74-A75.. 2013.
Transcriptional Profiling of RV144 Participants Reveals a Gene Expression Signature that Correlates with Immunogenicity. AIDS Research and Human Retroviruses. 29:A173-A174.. 2013.
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine.. The New England journal of medicine.. 2013.
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001).. The Journal of infectious diseases. 207(2):248-56.. 2013.